169 related articles for article (PubMed ID: 25536669)
1. The effect of recombinant human growth hormone with or without rosiglitazone on hepatic fat content in HIV-1-infected individuals: a randomized clinical trial.
Kotler DP; He Q; Engelson ES; Albu JB; Glesby MJ
Antivir Ther; 2016; 21(2):107-16. PubMed ID: 25536669
[TBL] [Abstract][Full Text] [Related]
2. Recombinant human growth hormone and rosiglitazone for abdominal fat accumulation in HIV-infected patients with insulin resistance: a randomized, double-blind, placebo-controlled, factorial trial.
Glesby MJ; Albu J; Chiu YL; Ham K; Engelson E; He Q; Muthukrishnan V; Ginsberg HN; Donovan D; Ernst J; Lesser M; Kotler DP
PLoS One; 2013; 8(4):e61160. PubMed ID: 23593417
[TBL] [Abstract][Full Text] [Related]
3. Effect of Recombinant Human Growth Hormone and Rosiglitazone for HIV-Associated Abdominal Fat Accumulation on Adiponectin and other Markers of Inflammation.
Leung V; Chiu YL; Kotler DP; Albu J; Zhu YS; Ham K; Engelson ES; Hammad H; Christos P; Donovan DS; Ginsberg HN; Glesby MJ
HIV Clin Trials; 2016 Mar; 17(2):55-62. PubMed ID: 27077672
[TBL] [Abstract][Full Text] [Related]
4. Long-term high-physiological-dose growth hormone reduces intra-abdominal fat in HIV-infected patients with a neutral effect on glucose metabolism.
Hansen BR; Haugaard SB; Jensen FK; Jensen JE; Andresen L; Iversen J; Andersen O
HIV Med; 2010 Apr; 11(4):266-75. PubMed ID: 20002779
[TBL] [Abstract][Full Text] [Related]
5. Combined effects of rosiglitazone and conjugated linoleic acid on adiposity, insulin sensitivity, and hepatic steatosis in high-fat-fed mice.
Liu LF; Purushotham A; Wendel AA; Belury MA
Am J Physiol Gastrointest Liver Physiol; 2007 Jun; 292(6):G1671-82. PubMed ID: 17322064
[TBL] [Abstract][Full Text] [Related]
6. Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio.
Mulligan K; Yang Y; Wininger DA; Koletar SL; Parker RA; Alston-Smith BL; Schouten JT; Fielding RA; Basar MT; Grinspoon S
AIDS; 2007 Jan; 21(1):47-57. PubMed ID: 17148967
[TBL] [Abstract][Full Text] [Related]
7. Rosiglitazone in the treatment of HAART-associated lipodystrophy--a randomized double-blind placebo-controlled study.
Sutinen J; Häkkinen AM; Westerbacka J; Seppälä-Lindroos A; Vehkavaara S; Halavaara J; Järvinen A; Ristola M; Yki-Järvinen H
Antivir Ther; 2003 Jun; 8(3):199-207. PubMed ID: 12924536
[TBL] [Abstract][Full Text] [Related]
8. Insulin resistance, hepatic lipid and adipose tissue distribution in HIV-infected men.
He Q; Engelson ES; Ionescu G; Glesby MJ; Albu JB; Kotler DP
Antivir Ther; 2008; 13(3):423-8. PubMed ID: 18572755
[TBL] [Abstract][Full Text] [Related]
9. Low-dose growth hormone therapy reduces inflammation in HIV-infected patients: a randomized placebo-controlled study.
Lindboe JB; Langkilde A; Eugen-Olsen J; Hansen BR; Haupt TH; Petersen J; Andersen O
Infect Dis (Lond); 2016; 48(11-12):829-37. PubMed ID: 27417288
[TBL] [Abstract][Full Text] [Related]
10. Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure.
Johannsson G; Mårin P; Lönn L; Ottosson M; Stenlöf K; Björntorp P; Sjöström L; Bengtsson BA
J Clin Endocrinol Metab; 1997 Mar; 82(3):727-34. PubMed ID: 9062473
[TBL] [Abstract][Full Text] [Related]
11. Low-dose growth hormone treatment with diet restriction accelerates body fat loss, exerts anabolic effect and improves growth hormone secretory dysfunction in obese adults.
Kim KR; Nam SY; Song YD; Lim SK; Lee HC; Huh KB
Horm Res; 1999; 51(2):78-84. PubMed ID: 10352397
[TBL] [Abstract][Full Text] [Related]
12. Low-dose growth hormone treatment combined with diet restriction decreases insulin resistance by reducing visceral fat and increasing muscle mass in obese type 2 diabetic patients.
Nam SY; Kim KR; Cha BS; Song YD; Lim SK; Lee HC; Huh KB
Int J Obes Relat Metab Disord; 2001 Aug; 25(8):1101-7. PubMed ID: 11477493
[TBL] [Abstract][Full Text] [Related]
13. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.
Falutz J; Potvin D; Mamputu JC; Assaad H; Zoltowska M; Michaud SE; Berger D; Somero M; Moyle G; Brown S; Martorell C; Turner R; Grinspoon S
J Acquir Immune Defic Syndr; 2010 Mar; 53(3):311-22. PubMed ID: 20101189
[TBL] [Abstract][Full Text] [Related]
14. Low-dose recombinant human growth hormone as adjuvant therapy to lifestyle modifications in the management of obesity.
Albert SG; Mooradian AD
J Clin Endocrinol Metab; 2004 Feb; 89(2):695-701. PubMed ID: 14764783
[TBL] [Abstract][Full Text] [Related]
15. Visceral obesity, impaired glucose tolerance, metabolic syndrome, and growth hormone therapy.
Attallah H; Friedlander AL; Hoffman AR
Growth Horm IGF Res; 2006 Jul; 16 Suppl A():S62-7. PubMed ID: 16624603
[TBL] [Abstract][Full Text] [Related]
16. Growth hormone axis treatments for HIV-associated lipodystrophy: a systematic review of placebo-controlled trials.
Sivakumar T; Mechanic O; Fehmie DA; Paul B
HIV Med; 2011 Sep; 12(8):453-62. PubMed ID: 21265979
[TBL] [Abstract][Full Text] [Related]
17. Effects of recombinant growth hormone on visceral fat accumulation: pilot study in human immunodeficiency virus-infected adolescents.
Viganò A; Mora S; Manzoni P; Schneider L; Beretta S; Molinaro M; di Natale B; Brambilla P
J Clin Endocrinol Metab; 2005 Jul; 90(7):4075-80. PubMed ID: 15840750
[TBL] [Abstract][Full Text] [Related]
18. Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection.
Engelson ES; Glesby MJ; Mendez D; Albu JB; Wang J; Heymsfield SB; Kotler DP
J Acquir Immune Defic Syndr; 2002 Aug; 30(4):379-91. PubMed ID: 12138344
[TBL] [Abstract][Full Text] [Related]
19. Impact of rosiglitazone on body composition, hepatic fat, fatty acids, adipokines and glucose in persons with impaired fasting glucose or impaired glucose tolerance: a sub-study of the DREAM trial.
Punthakee Z; Alméras N; Després JP; Dagenais GR; Anand SS; Hunt DL; Sharma AM; Jung H; Yusuf S; Gerstein HC
Diabet Med; 2014 Sep; 31(9):1086-92. PubMed ID: 24890138
[TBL] [Abstract][Full Text] [Related]
20. The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation.
Lo JC; Mulligan K; Noor MA; Schwarz JM; Halvorsen RA; Grunfeld C; Schambelan M
J Clin Endocrinol Metab; 2001 Aug; 86(8):3480-7. PubMed ID: 11502767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
